The role of Lymphotoxin-β in Cetuximab resistance of head and neck cancer
碩士 === 國立陽明大學 === 臨床醫學研究所 === 103 === Cetuximab, a monoclonal antibody against the epidermal growth factor receptor EGFR extracellular domain, has been approved for the treatment of head and neck squamous cell carcinomas (HNSCC). However, many patients acquire resistance after Cetuximab treatment. T...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en_US |
| Published: |
2015
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/2f2vb3 |